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Although anemia is commonly observed in pa-
tients with sepsis or other severe infections   
(Vincent et al., 2002; Corwin et al., 2004; Walsh 
and Saleh, 2006; Napolitano et al., 2009), the 
connection  between  acute  inflammation  and 
cytopenias is not well understood. Although ane-
mia in some acutely ill patients may be a result 
of obvious causes such as blood loss, hemodilu-
tion, or microangiopathic hemolysis, the etiol-
ogy is often unknown (Abshire, 1996; Ballin et al., 
2009; Rivera and Ganz, 2009). There is a critical 
need to better understand acute inflammation-
associated cytopenias; however, because unex-
plained early cytopenias are associated with a 
poor prognosis in patients presenting with sepsis 
and other infections (Imran et al., 2005; Bateman 
et al., 2008; Reade et al., 2010). Unlike acutely 
developing cytopenias, anemias associated  with 
chronic inflammation (anemia of chronic dis-
ease) have been extensively studied and are 
known to be caused by decreased production of 
erythrocytes (Agarwal and Prchal, 2009).
Unexplained acute cytopenias are also seen 
in the disorder hemophagocytic lymphohistio-
cytosis (HLH), which is a disease of excessive and 
abnormal immune activation associated with de-
ficiencies  of  lymphocyte  cytotoxic  function 
(Filipovich, 2008). Development of cytopenias 
in these patients may be quite rapid, suggesting 
a  consumptive  etiology  (although  anti-RBC 
antibodies or hemolysis are not typically noted; 
Henter et al., 1998). The pathology seen in HLH 
is thought to be the result of a storm of inflam-
matory cytokines, including IFN- (Henter et al., 
1991; Janka and zur Stadt, 2005; Janka, 2007), 
which has been correlated with poor prognosis 
(Henter et al., 1991; Ohga et al., 1993; Imashuku 
et al., 1994) and is necessary for the develop-
ment of HLH in murine models (Jordan et al., 
2004; Pachlopnik Schmid et al., 2009).
Hemophagocytosis (blood eating) is a term 
used to describe the histological appearance of 
macrophages  engulfing  blood  cells. Although 
hemophagocytosis is characteristic of HLH, it is 
also seen in many instances of severe inflamma-
tion such as bacterial sepsis (Ito et al., 2006), in-
fluenza (Ando et al., 2006; Hsieh and Chang, 
2006), malaria (Ohno et al., 1996; Zvulunov et al., 
2002), leishmaniasis (Agarwal et al., 2006), and 
active rheumatologic disorders (Behrens et al., 
2007; Parodi et al., 2009; Hinze et al., 2010). 
Although hemophagocytic macrophages are sus-
pected to contribute to the development of 
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Cytopenias of uncertain etiology are commonly observed in patients during severe inflammation. 
Hemophagocytosis, the histological appearance of blood-eating macrophages, is seen in the 
disorder hemophagocytic lymphohistiocytosis and other inflammatory contexts. Although it is 
hypothesized that these phenomena are linked, the mechanisms facilitating acute inflamma-
tion-associated cytopenias are unknown. We report that interferon  (IFN-) is a critical driver 
of the acute anemia observed during diverse microbial infections in mice. Furthermore, systemic 
exposure to physiologically relevant levels of IFN- is sufficient to cause acute cytopenias and 
hemophagocytosis. Demonstrating the significance of hemophagocytosis, we found that IFN- 
acts directly on macrophages in vivo to alter endocytosis and provoke blood cell uptake, leading 
to severe anemia. These findings define a unique pathological process of broad clinical and 
immunological significance, which we term the consumptive anemia of inflammation.
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was vital to the development of disease-associated pathologies. 
To  test  this,  Prf1/  mice  that  were  also  IFN-  deficient 
(Prf1//Ifng/) were infected with LCMV (Fig. 1 a). On 
day 15 of infection, hemoglobin levels were assessed and we 
found that Prf1//Ifng/ mice were strikingly protected from 
the severe anemia seen in LCMV-infected Prf1/ mice. In   
addition, WT mice (which have peak IFN- levels of 1,000–
2,000  pg/ml  after  infection,  compared  with  Prf1/  mice 
with peak levels >10,000 pg/ml; Jordan et al., 2004) also devel-
oped anemia, albeit much milder.
The anemia observed in WT mice suggested that this   
process was not specific to Prf1/ mice but was simply 
heightened by their excessive IFN- production. To test this 
hypothesis, WT mice were infected with Toxoplasma gondii 
(which is known to drive high serum levels of IFN- and has 
been reported to cause anemia; Mullarky et al., 2007) and were 
given either neutralizing anti–IFN- or isotype control anti-
body 4–5 d after infection. The T. gondii infection led to peak 
IFN- levels of 5,000–7,000 pg/ml in the isotype-treated an-
imals (not depicted), and by day 9 or 10 these animals became 
severely anemic, a process which was prevented in the mice 
which received IFN-–neutralizing antibody (Fig. 1 b).
Observing IFN-–dependent acute anemia during two 
diverse infections, we hypothesized that IFN- would be 
sufficient, in the absence of infection, to induce rapid-onset 
anemia. To test this idea, IFN- was infused into uninfected 
animals via subcutaneously placed osmotic pumps to achieve 
various average serum levels over 5 d of infusion. We found 
that anemia developed in a dose-dependent fashion, reaching 
a plateau at a mean continuous exposure of 2,500 pg/ml   
(Fig. 1 c). Notably, this level is well within the physiological range 
of IFN- levels seen in LCMV-infected Prf1/ mice, T. gondii–
infected WT mice, or human patients with active HLH (Ohga 
et al., 1993; Imashuku et al., 1994, 1998; Jordan et al., 2004; 
Mullarky et al., 2007). Next, we assessed the kinetics of this 
response by infusing mice with IFN- to achieve levels of 
>2,500 pg/ml for various times. Over 5 d of IFN- infusion, 
WT mice developed severe anemia, which became apparent 
after 48 h of exposure (Fig. 1 d). In contrast, mice injected 
with a single large dose of IFN- (up to 100 µg i.p.) did not 
develop anemia on subsequent days (unpublished data), which 
may be related to the short half-life of IFN- (30 min in 
mice; Rutenfranz and Kirchner, 1988). The kinetics and se-
verity of anemia observed with IFN- infusion mimicked 
those seen after infection. WT mice infected with T. gondii or 
Prf1/ mice infected with LCMV did not display serum 
IFN- levels >2,500 pg/ml until day 4 or 6 of infection and 
did not develop anemia until after day 6 or 8 of infection, re-
spectively (Jordan et al., 2004; not depicted). Furthermore, the 
mild  (but  consistent)  anemia  observed  in  LCMV-infected 
WT mice correlated well with these kinetic data. Although 
these animals develop potentially pathological peak IFN- 
levels (1,000–2,000 pg/ml), this level was maintained for <48 h.
We measured red cell indices of IFN-–infused mice and 
found that they were relatively unchanged (Fig. S1). The ane-
mia that developed after IFN- infusion was a normocytic 
cytopenias seen in HLH, this link has not been demonstrated. 
Hemophagocytosis remains largely uncharacterized; the trig-
gers, the mechanisms by which hemophagocytic macrophages 
consume blood cells, and the consequences are all unknown.
Although IFN- has been linked to the pathogenesis of 
HLH in animal models, how it may be related to the phenom-
enon of hemophagocytosis is unknown. IFN- is known as a 
classical activator of macrophages, up-regulating antigen pre-
sentation and antimicrobial responses, including production 
of reactive oxygen species and induction of inducible nitric 
oxide synthase (Rosa et al., 1986; Cassatella et al., 1989; 
Kato et al., 1989; Deguchi et al., 1995; Boehm et al., 1997). 
Although cytopenias are not reported with typical intermittent 
dosing of IFN- (as used for certain immunodeficient patients; 
Marciano et al., 2004), early clinical trials using sustained 
infusions of the cytokine noted rapid induction of cytopenias 
in some recipients (Kurzrock et al., 1986; Quesada et al., 1987; 
Kuebler et al., 1990; Brown et al., 1991). Although IFN- is 
thought to suppress hematopoiesis (Zoumbos et al., 1984), the 
rapid onset of these cytopenias suggests a consumptive rather 
than hypoproductive etiology.
To better understand the mechanisms behind otherwise 
unexplained acute inflammation-associated cytopenias, we tested 
the hypothesis that hemophagocytosis is a significant cause of 
rapidly developing anemia and other cytopenias in severe in-
flammatory contexts. Furthermore, because of IFN-’s known 
role in HLH development, we hypothesized that it is the 
proximal cause of hemophagocytosis. To test these hypotheses, 
we examined various hematologic and histological parame-
ters in mice during infection or during sterile IFN- infu-
sion. We found that sustained systemic exposure of mice to 
IFN-, at physiological levels seen during diverse infections, 
is sufficient to cause a rapid-onset severe anemia. This anemia 
develops within days, defining it as a consumptive (as opposed 
to hypoproductive) process, and it occurs in the absence of 
apparent hemorrhage, autoantibodies, or hemolysis. However, 
it is associated with diffuse hemophagocytosis, and both the 
anemia and hemophagocytosis are dependent on the direct 
action of IFN- on macrophages in a STAT1- and IFN regu-
latory  factor  1  (IRF-1)–dependent  manner. Thus,  these 
studies mechanistically define a novel pathological process, 
which we term the consumptive anemia of inflammation 
(CAI; to distinguish it from the hypoproductive anemia of 
chronic diseases). Furthermore, they uncover a new mechanism 
for unexplained acute inflammation–associated cytopenias by 
identifying hemophagocytosis as the underlying immunopatho-
logic process.
RESULTS
Infection-associated inflammation leads to a severe 
consumptive anemia that is dependent on IFN-
We have previously demonstrated that lymphocytic chorio-
meningitis virus (LCMV)–infected perforin-deficient (Prf1/) 
mice exhibit the clinical characteristics of human HLH, in-
cluding high serum levels of IFN- and the development of 
pancytopenia (Jordan et al., 2004). We hypothesized that IFN- JEM Vol. 208, No. 6 
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one, with no notable changes in peripheral morphology other 
than a compensatory reticulocytosis, which was evident by 
day 5. In addition to anemia, IFN-–infused mice developed 
leukopenia, neutropenia, and thrombocytopenia within 2 d of 
initiating the infusion (Fig. S1). The severity and the rapid de-
velopment of the anemia defined it as a consumptive process 
rather than a result of decreased RBC production because 
murine RBCs have a lifespan of 40 d (Ishikawa-Sekigami   
et al., 2006; Kempe et al., 2006). Furthermore, the brisk reticu-
locytosis demonstrated that erythropoiesis was not significantly 
suppressed. The rapid onset of neutropenia and thrombocyto-
penia also suggested a consumptive process, but because of the 
shorter life spans of these blood elements it is difficult to rule 
out decreased production or trafficking (in the case of leuko-
cytes) as a cause of these cytopenias. Because of this, we focused 
subsequent studies on understanding the nature of the con-
sumptive anemia which develops in IFN-–exposed mice.
In each context (LCMV infection, T. gondii infection, and 
IFN- infusion), blood loss by internal hemorrhage in stool 
or urine was not detected (unpublished data). To rule out 
hemolysis as a likely cause of anemia, blood smear morphology, 
serum lactate dehydrogenase (LDH), and bilirubin levels, as 
well  as  RBC  autoantibodies  (direct  and  indirect  Coombs   
assay) were all assessed (Fig. S1 and Fig. S2). With the exception 
of a mild increase in LDH (which was much less than that 
seen in control mice with intravascular hemolysis induced by 
human serum; Ino et al., 1987), no evidence of a hemolytic 
process was detected after IFN- infusion. Of note, moderate 
elevations of LDH are commonly observed in patients with 
active HLH. Thus, a unique and severe consumptive anemia 
develops in response to sustained exposure to elevated levels 
of IFN-, a process which we have termed the CAI to distin-
guish it from the hypoproductive anemia associated with chronic 
inflammatory processes.
Systemic IFN- exposure induces hemophagocytosis in vivo
Because  we  observed  a  loss  of  almost  60%  of  circulating 
RBCs within 5 d, we reasoned that there should be evidence 
of RBC uptake in various tissues. First, we noted that spleens 
were enlarged, with an expansion of the red pulp/subcapsular 
space and a congested appearance of the red pulp of IFN-–
exposed animals (Fig. 2 a and Fig. S3). We also noted an in-
crease of macrophages in the liver and bone marrow, with a 
mild decrease of marrow cellularity (Fig. S3). Examination of 
spleen, liver, and bone marrow tissue sections, as well as cyto-
spins from each of these tissues, revealed many examples of 
hemophagocytosis (Fig. 2 b and Fig. S4). We quantitated he-
mophagocytosis in the spleen by flow cytometric staining for 
intracellular RBC antigen in macrophages (Fig. 2 c). Intracel-
lular localization of RBC antigen was assessed by first blocking 
surface-exposed antigen with saturating amounts of unlabeled 
antibody and then permeabilizing and staining (see Materials 
Figure 1.  Sustained elevation of IFN- induces a severe consump-
tive anemia in physiological contexts and doses. (a) Blood hemoglobin 
concentrations were determined in WT, Prf1/, and Prf1/Ifng/ mice 
before or 15 d after infection with LCMV. Data are mean values ± SEM. 
n = 5–9 mice per group combined from three experiments. *, P < 0.0001, 
compared with uninfected controls. (b) WT mice were left uninfected or were 
infected with T. gondii and, 4–5 d later, given either IFN-–neutralizing or 
isotype control antibody. 9 or 10 d after infection, hemoglobin concentra-
tions were determined. Data are mean values ± SEM. n = 8–9 mice per 
group combined from two experiments. *, P < 0.0001, compared with all 
other points; #, P < 0.0001, compared with uninfected controls. (c) Mice 
were infused with various amounts of IFN- to achieve a range of serum 
levels of IFN- (x axis) for 5 d before blood hemoglobin concentrations 
were determined. The leftmost trend line includes control infusion mice (as 
0 values). Each point represents an individual mouse. n = 53 mice. (d) WT 
mice were infused with saline or IFN- via osmotic pumps (to maintain 
levels >2,500 pg/ml in the IFN- group) and hemoglobin levels were 
assessed at the indicated times. Data are mean values ± SEM. n = 107 mice 
combined from five experiments. Zero time point represents mice that 
received no infusion. *, P ≤ 0.001, compared with control infusion.1206 Hemophagocytosis drives anemia during inflammation | Zoller et al.
more sensitive than light microscopy 
for detecting hemophagocytosis be-
cause cytospins of sorted F4/80+/TER-119+ cells revealed 
that only a fraction of these cells contained recognizable RBCs 
or nucleated cells, whereas nearly all appeared to be debris 
laden (unpublished data). Hemophagocytosis did not appear 
to be related to global increase in apoptosis because we did 
not observe a significant increase in apoptotic or necrotic 
splenocytes after IFN- infusion (unpublished data).
IFN- acts directly on macrophages to induce 
hemophagocytosis, leading to CAI
The kinetics of CAI and hemophagocytosis after IFN- infu-
sion suggested that hemophagocytosis was causing the ane-
mia we observed. Furthermore, the lack of widespread cell 
death or other changes in splenocytes or RBCs suggested that 
IFN- was acting primarily on macrophages to induce hemo-
phagocytosis, which led to CAI. To test these hypotheses, we 
developed a transgenic mouse, which we have previously de-
scribed, called the macrophages insensitive to IFN- (MIIG) 
mouse (Lin et al., 2009; Lykens et al., 2010). MIIG mice se-
lectively express a dominant-negative mutant IFN- receptor 
in macrophage lineage cells and have a near complete block-
ade of IFN- signaling in these cells, whereas other cell types 
are able to produce and respond normally to this cytokine. 
When we challenged MIIG mice with IFN- infusion, we 
and methods). Consistent with the normal function of the 
spleen as a grooming organ for circulating RBCs, a fraction of 
macrophages demonstrated readily detectable RBC antigen 
within them before IFN- infusion. However, after IFN- 
infusion or administration of anti-RBC antibody (Jordan et al., 
2003), most splenic macrophages were found to contain in-
tracellular RBC antigen (Fig. 2 c). For additional corrobora-
tion, nonopsonized fluorescently labeled RBCs were injected 
intravenously into mice and found to be taken up by macro-
phages in mice receiving IFN- infusions (Fig. 2 c). We ex-
amined several macrophage-specific markers to identify which 
cells were most readily taking up RBCs. Bright expression of 
the F4/80 marker correlated best with RBC uptake, suggest-
ing that splenic hemophagocytic macrophages are red pulp 
macrophages (not depicted; Schaller et al., 2002). Increased 
intracellular RBC antigen was detectable in splenic macro-
phages (F4/80hi) as early as 1 d after initiating IFN- infusion, 
i.e., preceding the onset of measurable anemia (Fig. 1 c and 
Fig. 2 d). Additionally, we found significant uptake of a neu-
trophil-specific antigen by F4/80hi macrophages after IFN- 
infusion (Fig. S4). This finding, and the appearance of nucle-
ated debris within hemophagocytic macrophages, suggested 
they were taking up other cell types in addition to RBCs. 
Notably, our flow cytometry–based assay appears to be much 
Figure 2.  Systemic IFN- exposure 
induces hemophagocytosis in vivo.  
(a and b) Brightfield micrographs of H&E-
stained sections from mice infused with or 
without IFN- for 5 d of spleen sections  
(a; bars, 200 µm) or cytospun F4/80hi spleen 
cells (b; bars, 10 µm). (c, Top) mice were 
given 5-d IFN- infusions, 5-d control infu-
sions, or injected with anti-RBC antibody  
1 d before analyzing spleen cells. Spleen 
cells were permeabilized and stained intra-
cellularly for RBC antigen (after blocking 
surface-exposed antigen with unlabeled 
antibody). (c, Bottom) Alternatively, RBCs 
were labeled with PKH26 and injected or 
not intravenously 24 h before spleen cell 
analysis. Dot plots are representative sam-
ples with mean percentages of n = 5–6 
mice per group from two combined experi-
ments (TER-119 staining) or n = 6–8 mice 
per group from three combined experiments 
(PKH26 labeling). Numbers represent the 
mean percentage TER+ or PKH+ of F4/80hi 
spleen cells ± SEM. (d) Mice were infused 
with IFN- for the indicated times and 
spleen cells were stained intracellularly (as 
in c) for RBC antigen. Data are mean values ± 
SEM. n = 6–11 mice per group combined 
from two experiments. *, P < 0.001  
compared with control infusion.JEM Vol. 208, No. 6 
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In macrophages, IFN- also prominently induces production 
of nitric oxide via the inducible nitric oxide synthase (NOS2) 
and reactive oxygen species, in part via Cybb (also called   
Gp91phox or NOX2). We tested the hypothesis that these clas-
sical IFN- signaling/response mediators are essential for CAI 
by challenging mice deficient in each of them. As expected, 
Stat1/ mice infused for 5 d with IFN- were completely 
protected from CAI (Fig. 4). Notably, Irf1/ mice were also 
protected from CAI after IFN- infusion, whereas Nos2/ and 
Cybb/ mice displayed only minimal or modest protection 
(Fig. 4). Together, these data indicate that proximal IFN- 
signaling mechanisms involving STAT1 and IRF-1 are neces-
sary for the development of CAI in mice, whereas classical 
IFN-–induced macrophage effector molecules do not ap-
pear to be essential.
Cell surface and endocytic changes  
in hemophagocytic macrophages
The appearance of widespread hemophagocytosis suggested 
that tissue macrophage phenotypes were significantly altered 
by IFN- infusion. However, when we examined F4/80hi 
macrophages, we found no significant alterations in cell sur-
face molecule expression beyond expected changes, such 
MHC up-regulation (unpublished data). However, after IFN- 
found that splenic macrophages from MIIG mice displayed 
no evidence of hemophagocytosis (Fig. 3 a). Thus, IFN- 
must act directly on macrophages in order for hemophago-
cytosis to be induced in vivo.
Next, we examined the induction of anemia in MIIG 
mice after IFN- infusion. When challenged with IFN- in-
fusion, we found that MIIG mice were completely protected 
from CAI (Fig. 3 b). As an additional control condition, we 
challenged MIIG mice with anti-RBC antibody to test whether 
these mice were capable of developing a macrophage-dependent 
anemia (Jordan et al., 2003). MIIG mice had an identical re-
sponse to that of WT animals to anti-RBC antibody injec-
tion, demonstrating that macrophages in these animals were 
capable of engulfing RBCs. This divergence between IFN-–
induced anemia and antibody-induced anemia led us to also   
examine Fcer1g/ mice, which have defective Fc receptor sig-
naling. When we challenged them with antibody injection, 
Fcer1g/  mice  were  largely  protected  from  antibody-driven 
anemia. However, Fcer1g/ mice developed CAI-like WT ani-
mals after IFN- infusion, demonstrating that hemophagocytosis 
is a distinct process from Fc receptor–mediated phagocytosis.
These findings demonstrate that hemophagocytic macro-
phages are more than just innocent bystanders during CAI, 
which  has  not  been  demonstrated  before.  Because  IFN- 
must act directly on macrophages to induce them to become 
hemophagocytic, and because CAI does not develop in the 
absence  of  this  process,  IFN-–activated  hemophagocytic 
macrophages appear to play a causal role in the induction of 
CAI. These findings are also consistent with our observation 
that hemophagocytosis precedes anemia in WT mice during 
IFN- infusion (Fig. 1 d and Fig. 2 d). Indeed, the fact that 
measurable hemophagocytosis precedes measurable anemia 
suggests that hemophagocytosis may be a rate-limiting step in 
the development of anemia.
Necessity of pathways downstream of the IFN- receptor
In all cell types, IFN- is known to signal through STAT1 
and to induce transcription of numerous genes, including that 
of the transcription factor IRF-1. In turn, IRF-1 directly induces 
a large proportion of IFN-–induced genes (Dror et al., 2007). 
Figure 3.  IFN- acts directly on macrophages to induce hemophagocytosis and CAI. (a) WT and MIIG mice, which selectively lack IFN- signaling 
in macrophage-lineage cells, were given IFN- or control infusions for 5 d and intracellular RBC antigen was assessed in splenic F4/80hi macrophages by 
flow cytometry. Histograms are representative of three experiments and are gated onF4/80hi cells. Bar graph data are mean values ± SEM. n = 5–14 mice 
per group combined from three experiments. (b) WT, Fcer1g/, and MIIG mice were challenged with IFN- infusion (for 5 d) or anti-RBC antibody, and 
blood hemoglobin concentration was determined. Data are mean values ± SEM. n = 7–18 mice per group combined data from two or more experiments. 
*, P < 0.0001 compared with control infusion.
Figure 4.  IFN-–driven CAI is STAT1 and IRF-1 dependent but 
largely NOS2 and Cybb independent. WT, Stat1/, and Irf1/, 
Nos2/, and Cybb/ mice were infused with IFN- over 5 d and blood 
hemoglobin concentrations were determined. Data are mean values ± 
SEM. n = 3–13 per group combined from two or more experiments.  
*, P ≤ 0.001 compared with control infusion1208 Hemophagocytosis drives anemia during inflammation | Zoller et al.
This finding is a novel one; IFN- has not previously been 
shown to influence macrophage pinocytosis. Similar increased 
fluid-phase uptake was also seen in peritoneal macrophages of 
IFN-–exposed mice when a soluble fluorescent dye (hydra-
zide salt of Alexa Fluor 647) was injected intraperitoneally 
(Fig. 6 and not depicted). In contrast, when we injected mice 
with fluorescent dextran, which is largely taken up via the 
macrophage mannose receptor, we saw no increase in uptake 
(Fig. S5), suggesting that IFN- exposure was not affecting all 
forms of macrophage endocytic uptake. Finally, injection of 
both labeled RBCs and fluid-phase markers showed that 
hemophagocytic macrophages were also the ones that most 
avidly took up fluid-phase markers in response to IFN- in-
fusion (Fig. 5 e). Collectively, these data indicate that IFN- 
induces an increase in pinocytosis, which is associated with 
hemophagocytosis in splenic macrophages.
Hemophagocytosis is a macropinocytic process
Endocytosis  may  be  divided  broadly  into  classical  ligand-
driven  phagocytosis  and  pinocytosis  (Amyere  et  al.,  2002; 
Conner and Schmid, 2003). Phagocytosis, a receptor-mediated 
process (e.g., Fc receptor or complement receptor), involves 
tight hugging of the cargo by the phagocyte’s membrane   
(a zipper-like mechanism) allowing little fluid-phase uptake.   
During pinocytosis, which is either spontaneous or induced 
by ligand/receptor stimulation, membrane extensions engulf 
infusion we observed that macrophages in the spleen and 
other tissues increased markedly in size and complexity/side 
scatter, as assessed by flow cytometry (Fig. 5 a). Microscopic 
examination of cytospun peritoneal macrophages from con-
trol and IFN-–infused mice confirmed an increase in size 
and also revealed a dramatic increase in membrane protru-
sions and ruffles (Fig. 5 b). Splenic macrophages (obtained 
after collagenase digestion of disrupted spleens) displayed a 
similar phenotype but with a more prominent foamy or vacu-
olated morphology and less obvious membrane protrusions 
(unpublished data). We quantitated this increase in membrane 
ruffling by measuring F-actin content of macrophages, which 
would be expected to increase with more active membrane 
dynamics. Because the formation and degradation of F-actin 
is a very dynamic process, we stained peritoneal macrophages 
which were fixed immediately after lavage. We found a clear 
increase in F-actin after IFN- infusion in these cells (Fig. 5 c). 
Based on their foamy appearance and increased membrane 
ruffling, we hypothesized that macrophages in IFN-–infused 
mice had increased fluid-phase endocytosis, or pinocytosis.   
To examine this possibility, we directly examined pinocytic 
uptake of (inert) fluid-phase markers in vivo. We found that 
IFN-  infusion  markedly  increased  uptake  of  fluid-phase 
constituents by splenic, hepatic, and peritoneal macrophages, 
as indicated by uptake of intravenously administered fluores-
cently labeled bovine albumin (Fig. 5 d and not depicted). 
Figure 5.  IFN- infusion leads to in-
creased size, membrane protrusions,  
F-actin assembly, and pinocytosis by macro-
phages. (a) 5 d after control or IFN- infu-
sion, F4/80hi gated spleen cells were assessed 
by flow cytometry for forward/side scatter. 
Dot plots are representative of three experi-
ments. (b) 3 d after control or IFN- infusion, 
mouse peritoneal cells were cytospun and 
stained for H&E. Bars, 10 µm. (c) 3 d after 
control or IFN- infusion, F-actin was mea-
sured in F4/80+ peritoneal cells by flow cyto-
metric phalloidin-A647 staining. Histograms 
are representative of three experiments.  
(d) WT mice infused with IFN- for 1 d were 
injected with a fluid-phase marker (BSA-
A647) and spleen cells were assessed 1 d later 
(while infusion continued) for uptake of this 
marker. Bar graph represents mean values ± 
SEM. n = 8–11 mice per group combined from 
three experiments. *, P < 0.001 compared with 
all conditions. (e) Mice infused with IFN- for 
1 d were injected intravenously with PKH26-
labeled RBCs along with BSA-A647 (as in d).  
1 d later (while infusion continued), F4/80hi 
gated spleen cells were assessed for combined 
RBC and fluid-phase uptake by flow cytom-
etry. Dot plots are representative two experi-
ments. Numbers represent mean percentage 
of BSA+ of hemophagocytic (PKH+) F4/80hi 
spleen cells. n = 3–6 mice per group com-
bined from two experiments.JEM Vol. 208, No. 6 
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fluid-phase markers and dye-labeled RBCs 
intraperitoneally  into  mice  that  had  re-
ceived either IFN- or control infusions. 
Peritoneal  macrophages  were  retrieved 
within 45 min and assessed using a flow 
microscopy technology to quantify colo-
calization  of  RBCs  and  fluid-phase  dye. 
Control animals were injected with a fluid-
phase marker along with dye-labeled apop-
totic cells, as an example of macropinocytic 
uptake, or IgG-opsonized RBCs, for classi-
cal FcR-mediated phagocytosis. As expected, 
the fluid-phase marker was substantially ex-
cluded from phagosomes containing opso-
nized  RBCs  but  was  incorporated  into 
endosomes containing apoptotic cells (Fig. 6, 
b and c). The endosomes containing hemo-
phagocytosed RBCs (nonopsonized RBCs, 
injected into IFN-–infused mice) incor-
porated the fluid-phase markers, similar to those containing 
apoptotic cells (Fig. 6, b and c). Collectively, these data dem-
onstrate that IFN-–induced hemophagocytosis is a macro-
pinocytic process, with similarities to apoptotic cell uptake.
DISCUSSION
In the current study, we have demonstrated that an IFN-–
dependent anemia develops acutely in the context of diverse 
infections or sterile cytokine infusion. This anemia is associated 
with the widespread appearance of hemophagocytosis in vivo, 
and both processes are dependent on IFN- signaling in mac-
rophage lineage cells. Furthermore, IFN-–triggered hemo-
phagocytosis  is  characterized  as  a  macropinocytic  process. 
These findings are summarized diagrammatically in Fig. S6. 
In addition to defining a new mechanism for the development 
cargo (which can include whole cells), incorporating some of 
the surrounding fluid phase into a loose pinosome (Fig. 6 a). 
Pinocytosis can be further divided into macro- and micro-
pinocytosis, depending on whether the cargo/pinosome is 
greater or smaller than 1 micron. One well studied macro-
pinocytic process is the uptake of apoptotic cells by phagocytes, 
which is sometimes referred to as efferocytosis (Hoffmann   
et al., 2001; Ogden et al., 2001; Gardai et al., 2005, 2006; 
Vandivier et al., 2006). Increased pinocytic uptake by hemo-
phagocytic macrophages led us to hypothesize that hemophago-
cytosis is also a macropinocytic process in which fluid-phase 
constituents are taken up along with the blood cells.
We examined fluid-phase incorporation into hemophago-
cytic endosomes during very short-term in vivo experiments 
to further define this process. For these studies, we injected 
Figure 6.  IFN-–induced hemophagocytosis is 
a macropinocytic process. (a) Depictions of fluid-
phase exclusion (classical ligand-driven phagocyto-
sis) versus fluid-phase inclusion (macropinocytosis). 
PKH26-labeled apoptotic cells or RBCs (with or 
without opsonizing antibody), along with a fluid-
phase marker (soluble Alexa Fluor 647), were in-
jected i.p. into mice which had been infused for 48 h 
with saline or IFN-. 45 min after injection, perito-
neal cavities were lavaged and F4/80hi cells were 
assessed for colocalization of fluid-phase marker 
and target cells. (b) Example images of peritoneal 
macrophages. Bar, 10 µm. (c) Histograms (gated on 
F4/80hi PKH+ A647+ cells) quantitating fluid-
phase inclusion (median intensity) in target cell–
containing endosomes (PKH minimum intensity 
mask, expanded 1 pixel), representative of three 
experiments. Bar graphs represent percentage of 
colocalization ± SD of the mean of fluid-phase and 
target cells, combining two experiments. *, P = 0.03, 
one-tailed Student’s t test.1210 Hemophagocytosis drives anemia during inflammation | Zoller et al.
assessment but appears to be the best tissue to examine in ex-
perimental animals. Our data also point to a third potential 
explanation for the variable clinical and experimental preva-
lence of hemophagocytosis; histologically demonstrable hemo-
phagocytosis may only be the tip of an iceberg of cellular 
engulfment. In our controlled experimental studies, we find that 
most splenic macrophages acquire RBC antigens after IFN- 
infusion. When examined microscopically, most of these same 
cells appear to be laden with unidentifiable debris, whereas a 
subset contain probable RBCs and only a fraction contain 
clearly recognizable RBCs or nucleated cells (Fig. 2 and not 
depicted). This finding suggests that variations in breakdown 
of engulfed cells may play a major role in the histological 
phenomenon of hemophagocytosis.
This study has significant implications for the develop-
ment of new translational therapies and for the deeper under-
standing of macrophage biology, immune-mediated pathologies, 
and hematologic processes. First, these studies provide a clear ra-
tionale for developing therapies that directly target IFN-– 
activated macrophages in patients with HLH and those with 
acute inflammation-associated cytopenias. Although inflam-
matory macrophages have been hypothesized to be important 
for the development of HLH and similar acute inflammatory 
pathologies (Abshire, 1996), their role has not been previously 
demonstrated. This study demonstrates, for the first time, the 
causal role of IFN-–activated hemophagocytic macrophages 
in driving cytopenias. Because this IFN-–driven pathologi-
cal process occurs in both mutant and normal mice, it appears 
to be a pathophysiologic process that can be triggered in any 
individual with sufficient immune activation. The broader 
relevance of these findings is underscored by the fact that in 
some case series, nearly one third of patients admitted to hos-
pital intensive care units with sepsis have unexplained cytope-
nias at presentation (Bateman et al., 2008), and such critically 
ill patients with early onset cytopenias or marrow hemo-
phagocytosis have been found to have inferior survival rates 
(Strauss et al., 2004). Thus, this study provides a rationale for 
assessing hemophagocytosis in these various disease states and 
targeting this process for potential therapeutic benefit.
Second, these studies have significant implications for a 
better understanding of how IFN- influences macrophage 
biology. Although IFN- has for many years been described 
as a classical activator of macrophages, our data suggest that 
prolonged in vivo exposure triggers an additional unique and 
unexpected phenotype. Although hemophagocytosis was not 
triggered by a single dose of IFN-, continuous exposure 
over 24 h led to widespread uptake of RBCs. Although these 
kinetics will need to be studied in further detail, they suggest 
that new gene expression or other complex feedback mecha-
nisms (Hu and Ivashkiv, 2009) may be driving the hemo-
phagocytic response. Future studies will be needed to better 
define such processes. The current studies also have significant 
implications for better understanding of how inflammation 
influences apoptotic cell uptake by macrophages. The process 
of hemophagocytosis bears similarities to efferocytosis (up-
take of apoptotic cells) in that they are both macropinocytic 
of  acute  inflammation-associated  cytopenias,  these  studies 
have provided the first evidence for the causal role of macro-
phages and the significance of hemophagocytosis in this path-
ological  process.  Critical  aspects  of  the  hemophagocytic 
response remain undefined, however. Future studies will focus 
on better understanding the receptors/ligands that are likely 
to govern uptake, as well as the signaling mechanisms down-
stream of STAT1 and IRF1 which drive hemophagocytosis. 
Although the current study has provided new mechanistic 
insights into poorly understood pathological processes, several 
caveats are applicable to our findings. First, although IFN-–
driven CAI is a profound cause of infection-associated ane-
mia in our studies, it is not likely to be the only cause of cytopenias 
in complex acutely ill patients. Other processes, such as blood 
loss, hemolysis, and/or decreased marrow output may be oc-
curring, depending on the clinical context. Future studies will 
be needed to determine the relative contribution of hemo-
phagocytosis/CAI to otherwise unexplained acute inflamma-
tion-associated cytopenias in human patients. Second, although 
we have demonstrated an essential role for IFN- in our stud-
ies, this does not rule out a potential role for other inflamma-
tory cytokines or mediators in acute inflammation-associated 
cytopenias. Indeed, Milner et al. (2010) have demonstrated 
that  IL-4  exposure  can  drive  hemophagocytosis  and  mild 
anemia in experimental animals. Although we have assessed 
IFN-’s role in diverse infections (viral and parasitic), future 
studies examining other infections or inflammatory contexts 
(e.g., bacterial pathogens) will be needed to define the unique-
ness  of  IFN-  for  promoting  CAI.  Third,  although  we   
conclude that hemophagocytosis is an essential part of IFN- 
–driven CAI, it remains possible that other IFN-–driven 
processes are contributing to the observed anemia. We con-
clude that hemophagocytosis is causal for CAI based on three 
lines of data: (1) these processes have the common mechanism 
that both are abolished in the absence of macrophage IFN- 
signaling;  (2)  hemophagocytosis  correlates  kinetically  with 
anemia, preceding it by 1 d and continuing during its devel-
opment; and (3) a massive number of RBCs are eliminated 
(1010) within 5 d of IFN- infusion and yet the only trace 
of this consumptive process is found intracellularly, within 
macrophages. Although hemophagocytosis is clearly impor-
tant for the development of CAI, these data do not formally 
exclude the possibility that other IFN-–driven macrophage-
mediated processes may also contribute to CAI.
A  final  caveat  for  interpreting  our  data  are  that  even 
though our flow cytometric assays reveal a global up-regulation 
of RBC uptake, the histological appearance of hemophago-
cytosis is notably variable in human patients with HLH   
(or acute inflammation-associated cytopenias). In the case of 
HLH, this may be a result of specific aspects of disease devel-
opment. It is commonly reported that hemophagocytosis is 
variably found at the onset of clinical disease but is readily 
demonstrated at later time points during active disease (Henter 
et al., 1998). Furthermore, the variable prevalence of hemo-
phagocytosis may be related to sampling error or limitations 
of clinical sampling. Spleen tissue is rarely available for clinical JEM Vol. 208, No. 6 
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examining peripheral blood from patients with HLH or those 
with systemic onset juvenile idiopathic arthritis have revealed a 
unique primitive erythropoietic signature (Hinze et al., 2010; 
Sumegi et al., 2011).This finding suggests that significant com-
pensation is occurring for (sometimes occult) hemophagocytosis. 
Over 60 yr ago, Alexander et al. (1956) found that red blood cell 
life spans were significantly shortened in patients with rheuma-
toid arthritis. Remarkably, this shortened half-life correlated 
with a marker of systemic inflammation (erythrocyte sedimen-
tation rate), both among patients and across time in individual 
patients. Although the anemia of chronic disease may also play 
a role in this patient population, such findings and our current 
data suggest that old assumptions about the physiology and pa-
thology of the hematopoietic system should be reexamined.
MATERIALS AND METHODS
Mice
All mouse experiments were approved by the Cincinnati Children’s Hospital 
Medical Center International Animal Care and Use Committee. All mice 
were on a C57BL/6 (WT) background.  WT, Irf1/, Prf1/, Ifng/, Nos2/, 
and Cybb/ mice were obtained from The Jackson Laboratory. MIIG mice 
were described previously (Lykens et al., 2010). Fcer1g/ mice were obtained 
from Taconic. Stat1/ mice are “Poison” mice (ENU mutagenesis-derived 
mutant with complete loss of STAT1 function) and were a gift from K. Hoebe 
(Cincinnati Children’s Hospital Medical Center, Cincinnati, OH).
Antibodies
In vivo antibodies. TER-119 and 34-3C (anti-RBC antibodies; Fossati- 
Jimack et al., 1999), 20LC (isotype), and XMG1.2 (anti–IFN-–neutralizing 
antibody) were purified from hybridoma supernatants.
Flow  cytometry. F4/80-bio (clone bm8) and streptavidin-PerCP (Bio-
Legend), streptavidin–Pacific blue (Invitrogen), TER-119-A647, and 20LC-
A647 were labeled with Alexa Fluor 647 per the manufacturer’s protocol 
(Invitrogen). Hybridomas were gifts from E. Janssen (Cincinnati Children’s 
Hospital Medical Center, Cincinnati, OH) and S. Izui (University of Geneva, 
Geneva, Switzerland).
In vivo infection models
LCMV propagated in BHK21 cells was titered using a standard plaque assay 
(Hildeman et al., 1997). For infection, mice were injected i.p. with 200 PFU 
LCMV-WE. T. gondii (ME49 strain) infections were produced by injecting 50 
cysts i.p. (purified from the brains of chronically infected mice). 0.5 mg of   
either 20LC (isotype control) or XMG1.2 (IFN-–neutralizing antibody) 
were injected i.p. T. gondii was a gift from A. Dias and J. Aliberti (both at 
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH).
Infusion of IFN- and induction of anemia
Infusion of IFN- (PeproTech) was achieved by filling 3- or 7-d ALZET os-
motic pumps (DURECT) with IFN- per the manufacturer’s instructions 
and placing them subcutaneously on the back of mice. Mice were bled <50 µl   
by tail every 2–3 d of infusion to measure serum levels of IFN- by standard 
ELISA techniques using anti–IFN- antibodies purified from hybridoma   
supernatants. As an alternative method for inducing anemia, 40–100 µg of 
TER-119/mouse (Fig. 3) or 150 µg of 34-3C/mouse (Fig. 2) were injected 
i.p. Mice were retroorbitally bled for complete blood count (CBC) analysis 
using a dedicated veterinary CBC machine (Hemavet950FS; Drew Scien-
tific). In all experiments, RBC numbers correlated with hemoglobin levels. 
No mouse was bled more than once for CBC tests. Serum LDH and total and 
direct bilirubin were measured by the Cincinnati Children’s Hospital Clinical 
Research Laboratory using a commercial blood chemistry analyzer. Comple-
ment-mediated hemolysis was induced by injecting 0.3 ml i.v. of freshly col-
lected human serum in to mice and waiting 30 min before collecting blood.
processes. Also, because IFN- has recently been demonstrated 
to increase apoptotic cell uptake by macrophages (Fernandez-
Boyanapalli et al., 2010), it is possible that IFN- plays a signifi-
cant role in altering apoptotic cell uptake in inflammatory 
environments. Although the proximal signals triggering cell 
uptake during hemophagocytosis are not known, engulfment is 
generally limited by “don’t eat me” signals that need to be ac-
tively circumvented or outweighed by “eat me” signals such as 
opsonization or phosphatidylserine exposure on the target cell 
(Oldenborg et al., 2000; Gardai et al., 2005). Induction of hemo-
phagocytosis may involve alterations of macrophage receptive-
ness to don’t eat me signals, which may also alter apoptotic   
cell uptake. Future studies examining these signals, as well as 
macrophage membrane/cytoskeletal dynamics (such as micro-
tubule formation; Binker et al., 2007) may deepen our under-
standing of the hemophagocytic response and other fundamental 
biological processes.
Third, the current study provides significant new insight 
into understanding how inflammation drives destructive pa-
thologies. The current study has defined a new form of immune-
mediated pathology, CAI, and defined its critical underlying 
mediators, signaling mechanisms, and cell types. Although our 
studies illustrate the pathological potential of IFN-–driven 
up-regulation of macrophage pinocytosis and hemophago-
cytosis, future studies may define the nonpathological role of 
this process in the immune response. IFN- generally acts lo-
cally (not as a hormone) and is secreted directionally from   
T cells toward interacting cells (Schroder et al., 2004; Huse et al., 
2006). This cytokine may commonly be sustained at high lev-
els in inflammatory microenvironments (undoubtedly above 
the threshold level for CAI we defined with systemic infu-
sion), triggering localized changes in macrophage endocyto-
sis. Perhaps only when such levels are sustained systemically, as 
occurs with certain infections or in individuals with HLH, 
the process becomes pathological. Although IFN- appears to 
be uniquely capable of driving CAI (Jordan et al., 2004), fur-
ther study will be required to determine whether other in-
flammatory cytokines may have similar effects or whether 
they may modify the effects of IFN-. However, because IFN- 
is both necessary for induction of anemia in the context of 
acute infection and sufficient to induce anemia (and other cyto-
penias) in uninfected animals, this cytokine may be contributing 
to pathological cytopenias in a variety of clinical conditions.
Finally, these studies have increased our understanding of 
hematologic dynamics. CAI is a unique process that is distinct 
from the anemia of chronic inflammation because the former 
is an acute and consumptive process, whereas the latter in-
volves alterations of iron metabolism and chronic suppression 
of hematopoiesis (Agarwal and Prchal, 2009). Even though 
IFN- may suppress hematopoiesis in certain contexts, our 
studies do not suggest that marrow suppression plays a signifi-
cant  role  in  the  cytopenias  we  observed  after  short-term 
IFN- exposure. The brisk reticulocytosis we observed after 
5 d of IFN- infusion also suggests that significant hemo-
phagocytosis may be occurring more commonly than is ap-
preciated in various clinical contexts. Gene expression studies 1212 Hemophagocytosis drives anemia during inflammation | Zoller et al.
antibody, as before, developed with VIP (purple color), and then stained with 
hematoxylin. All reagents for immunohistochemistry except for the primary 
antibodies were obtained from Vector Laboratories. Images were taken with 
either an AxioCam MRC-5 camera and AxioPlan2 microscope or an   
AxioCamICc3 camera on the Imager Z.1 microscope and analyzed with 
AxioVision 4.7 software (Carl Zeiss).
Quantitative fluorescent microscopy: ImageStream analysis
RBCs were obtained from untreated mice. Opsonized RBCs were incubated 
before injection for 45 min with 500 ng TER-119/107 RBCs. Apoptotic 
cells were the B0-97.10 T cell hybridoma cell line irradiated with UV light 
and incubated for 1 h at 37°C to achieve at least 40–50% annexin V (BD)–
positive  7AAD  (Sigma-Aldrich)-negative  cells.  107  pregroomed  PKH26- 
labeled RBCs (with or without opsonization) or 3 × 106 PKH26-labeled 
apoptotic cells were injected i.p into mice, along with 15 µg of the hydrazide 
salt of Alexa Fluor 647 (fluid-phase marker; Invitrogen). 45 min later, perito-
neal cavities were lavaged. RBCs were lysed and remaining cells were stained 
with F4/80. 2 × 105 cells were acquired on the ImageStream machine using 
the IDEAS software (Amnis Corporation) and analyzed using the ImageS-
tream INSPIRE software. Single focused F4/80+, PKH+, and A647+ cells 
with endosomes of a minimum PKH intensity were assessed. Colocalization 
of fluid-phase and ingested cells was determined by analyzing the image of 
the RBC-containing phagosome (PKH minimum intensity mask, expanded 
1 pixel) and measuring the median intensity of A647 signal.
Statistical analysis
All studies were repeated at least twice with consistent results and with a 
minimum of three mice per group, although typically more (as indicated in 
figure legends). All p-values were calculated using a two-tailed Student’s t test 
unless otherwise noted.
Online supplemental material
Fig. S1 shows CBC indices and RBC morphology after IFN- infusion. Fig. S2 
shows that IFN-–infused mice do not show evidence of a hemolytic process. 
Fig. S3 shows changes in morphology and cellularity of tissues after IFN- infu-
sion. Fig. S4 shows hemophagocytic macrophages from bone marrow, spleen, 
and liver, as well as macrophage intracellular staining for neutrophil antigen after 
IFN- infusion. Fig. S5 shows that IFN- infusion does not increase the uptake 
of dextran by splenic macrophages. Fig. S6 is a summary diagram of the mecha-
nisms of IFN-–induced hemophagocytosis and CAI. Online supplemental ma-
terial is available at http://www.jem.org/cgi/content/full/jem.20102538/DC1.
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